KNOW. PREVENT. FIND YOUR WAY.A non-profit information project
INFORMATION AND AWARENESS, TOGETHER.

INFORMATION AND GUIDANCE

Zelboraf therapy of metastatic melanoma accelerates cutaneous squamous-cell carcinomas and keratoacanthomas

Published: 16/10/2026

One study published in the New England Journal of Medicine Mutations  reports that mutation in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib. The molecular mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions

read more: RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

ADVERTISEMENT

Information, not a diagnosis.

These materials do not replace a medical consultation. If you notice a change or have concerns, seek medical advice.

ADVERTISEMENT